ACHE and Alzheimer disease: Thus, two hypotheses have been established—cholinergic hypothesis [127] and glutamatergic hypothesis [128], based on which FDA approved therapies—AchE inhibitors and NMDA receptor antagonists—to mitigate AD symptoms were developed.